Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mismatch Repair-Proficient Colorectal Cancer”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Looking for participantsNCT06792695
What this trial is testing

Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
AstraZeneca 80
Not applicableStudy completedNCT04482608
What this trial is testing

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

Who this might be right for
Colorectal Cancer MetastaticMismatch Repair DeficiencyMicrosatellite Instability High
Sun Yat-sen University 671
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07359456
What this trial is testing

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

Who this might be right for
Metastatic Colorectal Cancer
UNICANCER 130
Testing effectiveness (Phase 2)Looking for participantsNCT07735624
What this trial is testing

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Who this might be right for
Early Rectal CancerStage I Rectal CancerMicrosatellite Stable Rectal Carcinoma
Dana-Farber Cancer Institute 16
Testing effectiveness (Phase 2)UnknownNCT05160727
What this trial is testing

Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer

Who this might be right for
Mismatch Repair-proficientColorectal Cancer MetastaticMicrosatellite Stable
Zhejiang Cancer Hospital 44
Testing effectiveness (Phase 2)Study completedNCT02437136
What this trial is testing

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Who this might be right for
Non-Small Cell Lung CancerMelanomaMismatch Repair-Proficient Colorectal Cancer
Syndax Pharmaceuticals 191
Testing effectiveness (Phase 2)WithdrawnNCT05582031
What this trial is testing

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Who this might be right for
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more
Translational Research in Oncology
Testing effectiveness (Phase 2)Looking for participantsNCT07244705
What this trial is testing

ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Who this might be right for
Colorectal Cancer (Diagnosis)Colorectal Cancer MetastaticColorectal Cancer (CRC)+1 more
Anbogen Therapeutics, Inc. 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07175636
What this trial is testing

QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer (LARC)Mismatch Repair-Proficient (pMMR) Rectal CancerNon-metastatic Rectal Cancer
Sun Yat-sen University 66
Testing effectiveness (Phase 2)Looking for participantsNCT06567782
What this trial is testing

Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Who this might be right for
Neoplasms, Colon
GlaxoSmithKline 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07591597
What this trial is testing

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

Who this might be right for
Metastatic Colorectal NeoplasmsMicrosatellite Stable / Proficient Mismatch Repair Colorectal Cancer
National Cancer Center Hospital East 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT06356597
What this trial is testing

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Who this might be right for
Colorectal Cancer
Jing-yuan Fang, MD, Ph. D 33
Testing effectiveness (Phase 2)UnknownNCT05933980
What this trial is testing

Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerLiver MetastasesMSS
Sun Yat-sen University 44
Testing effectiveness (Phase 2)Study completedNCT02060188
What this trial is testing

Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Who this might be right for
Microsatellite Unstable Colorectal CancerMicrosatellite Stable Colorectal CancerMismatch Repair Proficient Colorectal Cancer+1 more
Bristol-Myers Squibb 385
Testing effectiveness (Phase 2)Looking for participantsNCT06856837
What this trial is testing

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

Who this might be right for
Metastatic Colorectal Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 140
Testing effectiveness (Phase 2)Study completedNCT04126733
What this trial is testing

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Who this might be right for
Colorectal Cancer
Bayer 70
Testing effectiveness (Phase 2)Study completedNCT02834052
What this trial is testing

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Who this might be right for
Metastatic Colon CancerSolid Tumor
Asha Nayak 42
Testing effectiveness (Phase 2)Looking for participantsNCT06522919
What this trial is testing

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticMicrosatellite Stable Colorectal CarcinomaRefractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Testing effectiveness (Phase 2)Looking for participantsNCT07079631
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
BioNTech SE 482
Large-scale testing (Phase 3)Not Yet RecruitingNCT06832917
What this trial is testing

Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)

Who this might be right for
Rectal Cancer
Wan He 238
Next Page
36